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population-based database of more than 170,000 patients in over 53 family practice 
clinics in southwestern Ontario, Canada were analyzed. These records contained 
chart-abstracted information such as visit diagnosis, BP, medications and consultation 
notes. The records from 10,120 adult non-diabetic patients who were diagnosed with 
hypertension and were initiated on treatment in 2005 and continued on monotherapy 
for at least 9 months were included. Hypertension was deﬁned as a BP exceeding 
140/90 mmHg, chart entry of a diagnosis of hypertension, or use of anti-hypertensive 
medication. The proportions of patients reaching target BP (BP less than 140/90 mmHg) 
were recorded. Due to the well known safety proﬁle of the compounds, a safety analy-
sis was not performed. RESULTS: After 9 months of treatment with monotherapy, 
the proportions of patients reaching target BP are as follows: 28% on ARBs compared 
to 27% on ACEIs (p  0.05), 26% on CCBs (p  0.05), 21% on BBs (p  0.002), and 
19% on diuretics (p  0.001). Within the ARB class, the proportions of patients 
reaching target BP are as follows: 38% on irbesartan compared to 32% on losartan 
(p  0.01), 9% on valsartan (p  0.001) and 25% on candesartan (p  0.001). CON-
CLUSIONS: In a real-world setting, similar proportion of patients treated with ARBs, 
ACEIs and CCBs monotherapy reached target blood pressure. Amongst the ARBs, a 
greater proportion of irbesartan-treated patients reached target BP. This analysis also 
shows that less than half of the patients treated with monotherapy reach target BP 
supporting the need for combination therapy in the management of hypertension in 
some patients.
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OBJECTIVES: To describe the methodology of a systematic review and meta-analysis          
evaluating the efﬁcacy and safety of anti-arrhythmic drugs (AADs) in the treatment 
of atrial ﬁbrillation (AF). Outcomes of interest included AF recurrence, cardiovascular 
(CV) morbidity, all-cause mortality, discontinuations, serious adverse events (SAE), 
persistence/compliance and health related quality of life (HRQoL). METHODS: Elec-
tronic databases (Cochrane Library, Medline, EMBASE; accessed March 2009) and 
manual bibliographic searches were conducted to identify relevant randomised clinical 
trials (RCTs). Comparators of interest included all AADs, rate and rhythm strategies 
or ablation in comparison with AADs. In addition to dronedarone, the primary AADs 
of interest were restricted to Class IC (ﬂecainide and propafenone) and Class III 
(amiodarone and sotalol). Relevant data were extracted by two independent reviewers. 
Data were analysed on an intention-to-treat basis and meta-analysis performed using 
the Peto odds ratio (OR)/ﬁxed-effect model. The Bucher method was employed for 
indirect comparisons. Direct comparisons and/or indirect comparisons via non-active 
control were conducted where appropriate, in relation to the outcomes of interest. 
RESULTS: In total, 145 separate publications met the pre-deﬁned inclusion criteria          
and were included in the systematic review. Of these, 71 were related to one of the 
ﬁve AADs of primary interest and were analysed. SAEs were reported in 24 pub-
lications, AF recurrence in 44, all-cause mortality in 52 and discontinuations in 62. 
Data relating to other morbidity outcomes such as hospitalisations or to persistence/
compliance and HRQoL were very limited; therefore, meta-analyses were not possible. 
These ﬁndings are consistent with results of a previous Cochrane review (2007). 
CONCLUSIONS: Based on the results of this current systematic review, limited meta-          
analyses were possible. The majority of studies were designed to assess AF recurrence 
only; therefore, few publications assessed relevant clinical markers of AF progression 
or complications such as CV morbidity.
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OBJECTIVES: Atrial ﬁbrillation (AF) is a potentially life-threatening arrhythmia. 
After restoration of a normal sinus rhythm, AF recurrence may be prevented with 
anti-arrhythmic drugs (AADs). The objective of this review was to evaluate the efﬁcacy     
of a novel AAD (dronedarone) and existing AADs with respect to mortality outcomes. 
METHODS: A systematic literature review was conducted of randomised clinical trials          
(RCTs) investigating the use of AADs in patients with AF. All-cause mortality and 
CV mortality data were extracted. Direct and indirect comparisons adopted an inten-
tion-to-treat basis using Peto odds ratios (OR) with a ﬁxed effect or Bucher model, 
respectively. RESULTS: The majority of published data considered dronedarone,       
amiodarone, sotalol, ﬂecainide or propafenone (32 publications). Peto ORs for all-
cause mortality at 12 months with 95% conﬁdence intervals (CI) for direct and indi-
rect comparisons via non-active control were calculated. In comparisons with 
non-active control, the risks of all-cause mortality were as follows: a signiﬁcant 
increase with sotalol (OR 2.72 [1.16, 6.38]); an increased trend with amiodarone and 
ﬂecainide, and a decreased trend, with a narrow CI, with dronedarone (OR 0.85 [0.66, 
1.09]). Indirect comparison demonstrated that dronedarone was associated with lower 
odds of all-cause mortality; this reached statistical signiﬁcance versus sotalol (OR 3.2 
[1.32, 7.78]). Indirect analysis of amiodarone versus dronedarone (OR 2.38 [0.80, 
7.07]) is consistent with the head-to-head DIONYSOS study (calculated OR 2.32 
[0.52, 10.32]). In both indirect and direct analyses, CIs for propafenone were too wide 
to interpret the results. Only one publication reported CV mortality data and this 
considered dronedarone. Therefore, meta-analyses were not possible. CONCLU-
SIONS: Clinical trial CV mortality data are limited. All-cause mortality does not           
appear to be signiﬁcantly reduced via the use of AADs. Despite this, the novel AAD, 
dronedarone, was associated with lower all-cause mortality risk than those observed 
with existing AADs or non-active control.
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OBJECTIVES: To explore variation in management of acute coronary syndromes 
(ACS), the commonest cardiac cause of hospital admission, and to measure quality of 
life (QoL) with the EQ-5D health state index at discharge. METHODS: A prospective, 
international, observational study recruited ACS patients undergoing percutaneous 
coronary intervention (PCI), April—November 2008, capturing practice patterns, 
resource use and QoL. RESULTS: 496 eligible ACS-PCI patients, 56% with unstable 
angina or non-ST-elevation MI (UA/NSTEMI) and 44% ST-elevation MI (STEMI) 
from Sweden (240), Finland (104), Norway (78) and Denmark (74) were included. 
The median age was 64 years (IQR: 56–72), 75% were male. 84% of patients got an 
aspirin loading dose (median 300 mg) and 95 % got clopidogrel (41% received 
a300 mg, 59% received 600 mg). Admission and discharge medications were: aspirin 
35 and 97%, clopidogrel 10 and 98%, statins 33 and 89%, beta-blockers 35 and 
83%. At admission 32% of patients used an ACE inhibitor, and there was some 
variation at discharge: Sweden and Finland: 73%, Norway 45%, Denmark 37%. 
Almost all patients (97%) had stents implanted. In Sweden 80%, in Finland 68%, in 
Norway 64%, and in Denmark 6% of patients got bare metal stents (BMS) only. Time 
from hospital admission to PCI: median 1 day (IQR 1–3 days) for UA/NSTEMI 
patients, (81% 3 days or less; Sweden-90%, Finland-82%, Norway-71%, Denmark-
57%). Almost all (97%) STEMI patients were treated within one day from admission. 
Total stay was median 4 days (IQR: 3–6) for both cohorts. The median (IQR) QoL 
at hospital discharge was overall: 0.85 (0.69–1.00), Sweden: 0.85 (0.73–1.00), 
Norway: 0.80 (0.69–1.00), Denmark: 0.87 (0.69–1.00), Finland: no data available. 
CONCLUSIONS: The use of pharmacotherapy in the Nordic countries was high. 
There was substantial variation in management of ACS patients for use of BMS. The 
QoL of patients at discharge was high in all countries.
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OBJECTIVES: Current European Society of Cardiology Guidelines recommend dual 
antiplatelet therapy for 12 months for all patients with acute coronary syndrome 
(ACS). Here we describe the 12-month antiplatelet treatment patterns in ACS patients 
undergoing percutaneous coronary intervention (PCI), and explore variations between 
three European countries. METHODS: The Antiplatelet Treatment Observational 
Registry (APTOR) is a prospective, international observational study that recruited 
ACS patients undergoing PCI in 2007–08, capturing practice patterns, resource use 
and QoL. RESULTS: A total of 1525 ACS-PCI patients were recruited: 38% patients 
presented with ST-elevation myocardial infarction (STEMI), 37% with non-ST eleva-
tion MI (NSTEMI), and 25% with unstable angina (UA). Follow-up data up to 12 
months are available for a total of 1335 (88%) patients. 97% of STEMI patients and 
93% of UA/NSTEMI patients reported using clopidogrel and aspirin after hospital 
discharge; overall clopidogrel use was 94% at discharge, 93% at 30 days, 78% at 6 
months, and 71% at 12 months. Dual clopidogrel and aspirin use at 12 months was 
overall: France 73%, Spain 69%, UK 63%; for STEMI patients, it was: France 74%, 
Spain 66%, UK 61%; for UA/NSTEMI patients: France 72%, Spain 71%, UK 64%; 
for patients with at least one drug eluting stent (DES): France 82%, Spain 82%, UK 
81%; for patients with bare metal stent (BMS) only: France 68%, Spain 38%, UK 
52%. CONCLUSIONS: These prospective data show some variations in the use of 
antiplatelet therapy between three European countries. While in patients with DES, 
one year use of dual oral antiplatelet therapy was similar across countries, in patients 
receiving a BMS only there was considerable variation between the countries. Anti-
platelet prescription cards should be considered.
